ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and
pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous
infusions in patients with chronic hepatitis C.